Picture the moment: someone has just been diagnosed, or their child has, or a parent’s diagnosis has upended the family’s plans for the next year. In the middle of that, a research coordinator hands them a document — twelve, fifteen, sometimes twenty pages — and asks them to read it, understand it, and sign it before they can enroll in a trial that might help.
That document is the informed consent form. And while it’s ultimately for the patient, the patient’s experience of actually reading and understanding it can get lost along the way.
Why Informed Consent Forms Fail the Patients Who Sign Them
An informed consent form has a lot of jobs to do. It has to accurately explain the study, disclose risks, capture required information, and give patients what they need to make an informed decision.
The challenge is that meeting all of those requirements doesn’t automatically make the final document easy to read or understand.
And it shows: most consent forms are written well above the average adult reading level. That’s not a new finding — health literacy researchers have been flagging it for decades — but the gap between “technically disclosed” and “actually understood” is still wide enough that patients regularly back out before signing, or sign without fully grasping what they’ve agreed to.
It’s worth resisting the urge to make this a villain story, though. The incentives are rational, even when the outcome isn’t:
- Sponsors and study teams translate a complex protocol into a consent form while making sure all required study information is included.
- Legal, regulatory and medical reviewers help make sure the language is accurate and meets applicable requirements.
- Sites/investigators may adapt the model form for local requirements and ultimately conduct the consent process with patients.
- IRBs review and approve the consent form before it can be used, including whether its language is appropriate for the intended population.
Every step in that process serves a purpose. But all of those reviews are still different from putting the finished form in front of real patients and seeing what they actually understand. A consent form can clear every required review and still fall short where it matters most: with the person being asked to sign it.
And that’s the gap: “understandable” as a standard isn’t always the same thing as understanding in practice.
How Consent Form Readability Impacts Clinical Trial Recruitment and Retention
When patients struggle to understand informed consent forms, it’s not just an ethical concern. It creates real business challenges for clinical trials, too.
When patients can’t easily understand what they’re agreeing to, the friction shows up everywhere clinical teams already feel pain: longer screening conversations, questions that could’ve been answered upfront, higher hesitation or withdrawal before enrollment completes — and, once enrolled, higher dropout when patients realize partway through what they’d actually signed up for.
It also compounds an issue the industry is actively trying to solve: trial diversity. Health literacy correlates with education, language access, and socioeconomic status — so a consent process built around dense, jargon-heavy English isn’t just inconvenient, it’s subtly filtering who finds a trial accessible enough to join. A recruitment strategy can be excellent at reaching a diverse patient population and still lose people at the consent step if the document itself is the barrier.
What Patient-Centered Informed Consent Looks Like
None of this requires choosing between regulatory rigor and patient understanding. The opportunity is to go beyond asking whether a form should be understandable and actually test how well patients understand it.
A few approaches already gaining traction:
- Plain-language standards: Writing to an 8th-grade reading level instead of defaulting to clinical or legal phrasing.
- Layered or tiered consent: Giving patients a concise, focused explanation of what matters most before they get into the full detail.
- Teach-back testing: Having patients explain the trial back in their own words before finalizing a form, to catch where understanding breaks down.
- Real patient review before launch: Testing consent language with actual patients from the relevant condition community, not just internal stakeholders.
That last one can close a gap the standard review process doesn’t always cover: seeing how the finished document actually lands with the people who will be asked to sign it.
How Patients Can Help Improve Informed Consent and Clinical Trial Enrollment
This is where patients themselves become the missing piece.
No one can tell you how a consent form actually lands with patients better than patients themselves. They can flag exactly where the language loses them, where a risk feels confusing or more alarming than intended, and where they’re left with questions the form was supposed to answer. That’s the kind of feedback a traditional document review can easily miss.
The catch: it requires access to the right patients before a form is finalized, not after enrollment stalls.
This is where platforms like Inspire can shift the picture. With direct access to millions of patients, sponsors can get consent language in front of real patients early, catching the phrases that confuse, the information that raises unexpected questions, and the sections people skim past entirely. The same community relationships that support recruitment can also help build a consent process that gives patients a clearer picture of what participation will actually involve.
The Goal Is an Informed Patient, Not Just a Signed Form
Informed consent has to meet regulatory requirements. But the point of those requirements isn’t the document itself. It’s the decision the patient is being asked to make.
A form can be accurate, complete, and approved and still be harder for a patient to understand than it needs to be. Sponsors and clinical teams that close that gap aren’t lowering the bar on compliance. They’re making the consent process work better for the person it exists for in the first place.
The question worth asking isn’t only, “Does this form disclose everything it needs to?” It’s also, “Could the person signing it explain back what participation will actually mean for them?”
If we haven’t tested that with patients, we don’t really know.
See how Inspire connects sponsors with real patient communities to test what’s landing before a form goes final.